24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Biopharma
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
14:40
Bazan returns to full capacity after Iran’s 2025 strike, despite new missile damage
14:15
Unity shuts down ironSource ad network, selling Supersonic three-and-a-half years after $4.4 billion merger
19:46
Israeli fuze maker Aryt rides arms boom with 300% revenue growth
19:04
“We delivered the Air Force the most advanced defense system in the world, but it does not become operational in one day”
More stories
Buzz
Most popular
Daily
Weekly
1
“We delivered the Air Force the most advanced defense system in the world, but it does not become operational in one day”
2
Iron Dome and Iron Beam developer Rafael targets fast-track IPO at over $20 billion valuation
3
New Grok Imagine limits spark user fury: Continues glitch or policy shift?
4
Zim seeks $924,000 bonus for CEO ahead of $4.2 billion sale
5
U.S. airlift and local production sustain Israel’s war effort
More news
Biopharma
6 stories about Biopharma
Biopharma company Short Wave partnering in clinical trial for eating disorders with Sheba Fund
16.08.22
|
CTech
The trial will study the safety and feasibility of psilocybin-assisted psychotherapy for the treatment of anorexia nervosa
SpliSense secures $28.5 million in funding to advance mRNA-altering pipeline for treatment of CF
13.05.21
|
Meir Orbach
The Israeli startup was founded by Prof. Batsheva Kerem, a renowned geneticist from the Hebrew University of Jerusalem, and its technology is based on her research
Israeli biopharma startup Omnix Medical awarded €10.8 million from EU to fight drug-resistant bacteria
26.01.21
|
Meir Orbach
The novel agents developed by Omnix are designed as an alternative to classical antibiotics
Nasdaq-Listed Biopharma Company Chiasma Raises $34.5 Million in Public Offering
09.04.19
|
CTech
Chiasma develops octreotide capsules for the treatment of acromegaly, a rare, chronic disease typically caused by a benign tumor of the pituitary gland
Gastro Treatment Company RedHill Wants to Raise $117 on Nasdaq
24.07.18
|
Lilach Baumer
The Tel Aviv-headquartered company announced on Monday that Nasdaq approved its listing on its second tier, the Global Market. RedHill's ADSs were previously listed on Nasdaq Capital Market
RedHill's Public Offering Spooks Investors, Sends Stock Down
09.11.17
|
Dror Reich
The Nasdaq-listed biopharmaceutical company priced its shares at $5.5 per American Depositary Share, a third of its 2015 public offering price, and dropped nearly 30% by Wednesday market close